arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Fortress Biotech, Inc.

FBIO
$2.34 ▼ -0.10 (-4.29%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
75 Visible periods
33 Metrics
Peer-ranked Benchmarks
Price Chart
40
Health
Weak
Moderately Bullish
auto_awesome

Analytical Summary

Fortress Biotech, Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $74.4M
Dividend Yield —
Revenue Growth 14.0% ↘
Op. Margin -53.5% ↘
ROIC -3.3% ↗
FCF / Share $-1.86 ↘
Trailing P/E —
Price / Book 0.5x
FCF Yield —
Debt / Equity 0.21
info Valuation on last close. End-of-day price, Sep 23, 2026.

75-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$18.72M
↑ +14.0% —
Net Income Profit after all expenses
$-468.00K
↓ -100.4% —
Operating Margin Operating profit as % of sales
-53.5%
↓ -10.8% 2th
FCF / Share Free cash flow per share
$-1.86
↓ -128.8% —
Long-Term Debt Long-term obligations
$35.00M
↓ -6.7% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
24
Returns
78
Financial Health ↑
31
Cash Quality
2

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 21 years · 75 quarters